TP53 and neoplasm: Most mutations in the oligomerization domain of p53 prevent its oligomerization, its binding to DNA, its transcriptional activity and are associated with tumor progression as occurs in patients with Li‐Fraumeni and Li‐Fraumeni‐like syndromes (Davison et al., 1998; Lomax et al., 1998).